Sara R. Fagerlie, PhD, CHCP www.onclive.com
ATLAS Analysis Supports KRd After ASCT in High-Risk, Newly Diagnosed Myeloma | OncLive
Carfilzomib, lenalidomide, and dexamethasone after transplant improved PFS and OS in high-risk, newly diagnosed multiple myeloma.
Cancer Communicator | Conference Hub
Feed on BlueskyFeeds Stats
- 💙 Liked by 0 users
- 📅 Updated 14 days ago
- ⚙️ Provider skyfeed.me
Cancer Conference Hub Likes over time
Like count prediction
The feed Cancer Conference Hub has not gained any likes in the last month.
Feed Preview for Cancer Conference Hub
Xavier Leleu, MD, PhD, gave a moving tribute to Frank Bridoux, MD, PhD, friend & colleague at the University Hospital Poitiers. Dr. Bridoux’s expertise included cast nephropathy & glomerulopathies, and seminal contributions in MGRS/MGCS. #IMS25
0
0
0
ATLAS Analysis Supports KRd After ASCT in High-Risk, Newly Diagnosed Myeloma #IMS2025 #mmsm #oncology www.onclive.com/view/atla….
0
0
0
Subcutaneous Isatuximab Delivery Is Noninferior to IV Administration in Multiple Myeloma @myeloma-society.bsky.social #IMS25 #mmsm www.onclive.com/view/subc….
www.onclive.com
Subcutaneous Isatuximab Delivery Is Noninferior to IV Administration in Multiple Myeloma | OncLive
Efficacy and pharmacokinetic measures with IV vs SC isatuximab delivered via an on-body injector were comparable in patients with multiple myeloma.
0
0
0
Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Newly Diagnosed Myeloma @myeloma-society.bsky.social #IMS25 #mmsm #hematology
www.onclive.com/view/dara….
www.onclive.com
Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Newly Diagnosed Myeloma | OncLive
Maintenance therapy with daratumumab plus lenalidomide led to higher MRD-negativity conversion rates vs lenalidomide alone in newly diagnosed myeloma.
0
0
0
Highlights from the 22nd IMS Annual Meeting
@myeloma-society.bsky.social
@rahulbanerjeemd.bsky.social @sridevirajeeve.bsky.social @vincentrk.bsky.social
oncodaily.com/voices/ims-3...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #MM #Myeloma #IMS #IMS25
oncodaily.com
Highlights from the 22nd IMS Annual Meeting - OncoDaily
Highlights from the 22nd IMS Annual Meeting / cancer, IMS 2025, International Myeloma Society, multiple myeloma, Myeloma, Myeloma Society, OncoDaily,
0
1
1
✨Join us in Hall FG for the conclusion of #IMS25!
12:00 PM ➡️ Highlights of the 2025 Annual Meeting
1:00 PM ➡️ Debate on ADCs, Bispecifics or CART
2:00 PM ➡️ Closing Ceremony
0
0
0
Functional high-risk (FHR) myeloma (relapse< 18 months) is an unmet medical need in MM. Katja Weisel, MD, spoke about how patients at FHR may be identified and encouraged CAR-T consideration for FHR patients at first relapse. #IMS25
0
0
2
It’s time for the morning abstracts! #IMS25
📍 Room 701 → Abstract Session 7
📍 Room 718 → Abstract Session 8
0
0
1
At #IMS25, Dr. Francesco Maura will present new research on the genomics that define neoplastic transformation in #multiplemyeloma precursor conditions. #mmsm
🗓️ Saturday, September 20 | 9:20 a.m. EDT
@mskcancercenter.bsky.social @myeloma-society.bsky.social @szusmani.bsky.social
0
0
0
It’s the final day of #IMS25! Check the program for today’s highlights and don’t miss the Debate on ADCs, Bispecifics or CART later today! bit.ly/3K8T4QU
0
0
1
Belantamab Mafodotin/Bortezomib/Dexamethasone Yields PFS, OS Benefits in Lenalidomide-Refractory Myeloma @myeloma-society.bsky.social
#IMS25 #mmsm #hematology
www.onclive.com/view/bela….
www.onclive.com
Belantamab Mafodotin/Bortezomib/Dexamethasone Yields PFS, OS Benefits in Lenalidomide-Refractory Myeloma | OncLive
Treatment with BVd led to favorable survival outcomes and prolonged responses vs DVd in lenalidomide-refractory patients with multiple myeloma.
0
0
0
Stretched Dosing Schedule of Belantamab Mafodotin Plus VRd Is Active, Safe in Transplant-Ineligible Myeloma #IMS2025 #mmsm #oncology www.onclive.com/view/stre….
www.onclive.com
Stretched Dosing Schedule of Belantamab Mafodotin Plus VRd Is Active, Safe in Transplant-Ineligible Myeloma | OncLive
The addition of belantamab mafodotin to standard-of-care VRd proved feasible as frontline therapy in newly diagnosed multiple myeloma.
0
0
0
A multi-stakeholder panel discussed a recent EMA-IMS-EHA survey on the attitudes of clinicians and regulators on MRD as an efficacy endpoint in myeloma, nuances of US & EU perspectives, & transplant-eligibility for patient stratification. #IMS25
0
1
2
Daratumumab/Ixazomib Quadruplet Yields Durable Efficacy in Transplant-Ineligible or-Deferred, Newly Diagnosed Myeloma @andrew02114.bsky.social @myeloma-society.bsky.social #IMS25 #mmsm #hematology
www.onclive.com/view/dara….
www.onclive.com
Daratumumab/Ixazomib Quadruplet Yields Durable Efficacy in Transplant-Ineligible or-Deferred, Newly Diagnosed Myeloma | OncLive
Daratumumab, lenalidomide, ixazomib, and dexamethasone was efficacious in transplant-ineligible, newly diagnosed myeloma.
0
0
0
Josefine Krüger, MD, IMS Riney CD Awardee, identified a previously unknown cereblon-independent mechanism of proteasomal degradation of IKZF1 (Ikaros) transcription factor, a key target of immunomodulatory drugs. #IMS25
0
1
2
With support from the Paula and Rodger Riney Foundation, the IMS has now funded 89 Translational and Career Development Awards, totaling $16 million over the past 5 years, in 66 Institutions across 25 countries. --Bobby Sandage, Jr, PhD #IMS25
0
0
1
Mala Shanmugam, PhD, IMS Riney TR Awardee, spoke about the impact of elevated heme exposure on modulation of T cell behavior and the balance between exhaustion and effector memory/terminally differentiated phenotypes. #IMS25
0
0
0
The IMS and the global myeloma community is deeply appreciative of the generosity, tireless dedication, and enduring support of Paula and Rodger Riney, and the Paula and Rodger Riney Foundation. #IMS25
0
1
2
Belantamab Mafodotin Triplet Yields Responses With Low Ocular Toxicity in Intermediate-Fit or Frail Newly Diagnosed Myeloma @myeloma-society.bsky.social #IMS25 #mmsm #hematology
www.onclive.com/view/bela….
www.onclive.com
Belantamab Mafodotin Triplet Yields Responses With Low Ocular Toxicity in Intermediate-Fit or Frail Newly Diagnosed Myeloma | OncLive
Belantamab mafodotin plus lenalidomide and dexamethasone induced CRs or better in over half of patients with newly diagnosed multiple myeloma.
0
0
0
Coming up at 5:30 PM📍Hall FG → Industry Symposium supported by Gilead & Kite and Arcellx. #IMS25
0
0
0